Related Experiment Video

Updated: May 5, 2026

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
05:37

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration

Published on: May 31, 2018

11.9K

Curcumin protects against acetaminophen-induced apoptosis in hepatic injury

Gang Li1, Jun-Bao Chen, Chao Wang

  • 1Gang Li, Jun-Bao Chen, Chao Wang, Zhi Xu, Hao Nie, Xiao-Yan Qin, Xiao-Mei Chen, Quan Gong, Department of Immunology, School of Medicine, Yangtze University, Jingzhou 434023, Hubei Province, China.

World Journal of Gastroenterology
|November 22, 2013
PubMed
Abstract

Insights

Curcumin (CMN) effectively protects against acetaminophen (APAP)-induced liver injury in mice. Both pre- and post-treatment with CMN significantly reduced liver damage markers and apoptosis, highlighting its therapeutic potential.

Area of Science:

  • Pharmacology
  • Hepatology
  • Toxicology

Background:

  • Acetaminophen (APAP) overdose is a leading cause of acute liver failure.
  • Curcumin (CMN), a natural compound, possesses known anti-inflammatory and antioxidant properties.
  • Investigating CMN's protective effects against APAP-induced hepatotoxicity is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy of curcumin (CMN) in mitigating liver injury caused by acetaminophen (APAP) in a murine model.
  • To assess the impact of CMN on key biomarkers of hepatic damage and oxidative stress following APAP challenge.

Main Methods:

  • Male mice were administered APAP (300 mg/kg) and treated with varying doses of CMN (10 or 20 mg/kg) either before or after APAP exposure.
  • Control groups received vehicle (carboxymethylcellulose or PBS) instead of CMN.
  • Liver injury was assessed by measuring serum alanine aminotransferase (ALT) levels, liver malondialdehyde (MDA) and superoxide dismutase (SOD) activity, and hepatocyte apoptosis.

Main Results:

  • Curcumin treatment significantly reduced serum ALT levels and liver necrosis compared to the APAP-only group.
  • CMN administration, particularly at 20 mg/kg, decreased MDA accumulation and increased SOD activity, indicating reduced oxidative stress.
  • Curcumin effectively inhibited APAP-induced hepatocyte apoptosis by modulating the Bcl-2/Bax ratio.

Conclusions:

  • Curcumin demonstrates significant hepatoprotective effects against APAP-induced liver injury in vivo.
  • CMN exhibits therapeutic potential for treating APAP-induced hepatotoxicity and potentially other forms of liver disease.
Keywords:
AcetaminophenAcute hepatic injuryApoptosisCurcuminFree radicals

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
100
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
437